Harmony Biosciences Holdings, Inc.
HRMYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. At a $2.45B market cap, Harmony Biosciences Holdings, Inc. ranks as a mid-cap company within healthcare. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Market Cap
$2.45B
Beta
0.93
P/E (TTM)
13.61
P/E (Fwd)
6.29
EPS (TTM)
$3.09
EPS (Fwd)
$6.69
ROE
20.5%
ROA
11.6%
Cash
$667.8M
Total Debt
$160.2M
Free CF
$182.8M
52W Change
27.2%
Annual Financials
Cash vs Debt
Where HRMY stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HRMY finished 29.17% above its 150-day moving average ($33.18) and 25.51% above its 200-day moving average ($34.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HRMY overbought or oversold?
At the September 3, 2026 close, HRMY's RSI(14) was 71.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Harmony Biosciences Holdings, Inc. holds $667.8M in cash against $160.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $182.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 20.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 11.6% further supports the picture of efficient asset utilization. Revenue has grown from $437.9M (2022) to $868.5M (2025), reflecting a 98% increase over the period.
With cash comfortably exceeding debt, HRMY has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Harmony Biosciences Holdings, Inc. and its sector.